About me
I am a health economist and British Academy Postdoctoral Fellow at the Department of Economics & Public Policy, Imperial College London, where I lead an independent three-year research programme on drug repurposing. My research focuses on pharmaceutical innovation, health technology assessment (HTA) and access to medicines.
Before the fellowship, I was a Postdoctoral Research Associate at Imperial College London, where I was co-investigator on a Gatsby Foundation project on the productivity of UK biopharmaceutical R&D and contributed to the EU-funded Hi-Prix project on pharmaceutical innovation and equitable access. I completed my ESRC-funded PhD at the London School of Economics, studying the role of patient organisations in innovation and access to medicines for rare diseases.
My work uses both quantitative and qualitative methods, including econometrics, survival analysis, document analysis and interviews. It has been published in journals such as The Lancet Oncology, The BMJ, Social Science & Medicine and Value in Health, and has been covered by The Observer. Beyond academia, I have worked as a health economist at NICE, as a consultant for the World Bank, and in health economics and market access consultancies.
Contact
Research
My research asks how policy, institutions and stakeholders shape which medicines are developed, how they are valued, and who gets access to them.
Current and recent projects
Awards and funding
- British Academy Postdoctoral Fellowship, 2026
- Highly Commended, LSE Class Teacher Awards, 2023–24
- “Italy Made Me” award for outstanding research by Italian early-career researchers in the UK, 2023
- ESRC Doctoral Training Partnership studentship, 2020–2024
Publications
For an up-to-date list with citations, see my Google Scholar profile.
Peer-reviewed articles
- Patient organizations involvement in healthcare: a rapid review and conceptual framework
- Conflicts of interest in FDA advisory committees: a systematic literature review
- Expanding access to NCD services via community retail pharmacies in LMICs: a systematic review of the literature
- Rare disease policy in high-income countries: an overview of achievements, challenges, and solutions
- How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals
- Managing experts’ conflicts of interest in the EU Joint Clinical Assessment
- A retrospective comparative analysis of the clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the US, Canada, England, and Scotland
- The role of patient organisations in research and development: evidence from rare diseases
- Algorithms and heuristics of health technology assessments: a retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries
- Industry funding of patient organisations in the United Kingdom: a retrospective study of commercial determinants, funding concentration and disease prevalence
- Safeguarding NICE from patient groups’ conflicts of interest
- The cost-effectiveness of nintedanib versus pirfenidone in idiopathic pulmonary fibrosis in Belgium
Under review
- Do policy incentives align with pharmaceutical innovation challenges? A retrospective analysis of 42 countries (2000–2022)
Selected reports and abstracts
- Incentives for pharmaceutical innovation and equitable access to innovation
- Cost-effectiveness of vagus nerve stimulation for treatment-resistant depression in the United Kingdom
- Network meta-analysis comparing palbociclib plus fulvestrant with everolimus plus exemestane for HR+/HER2- advanced breast cancer resistant to previous endocrine therapy
Media coverage
Teaching
University of Bologna
Imperial College London
- Health Economics (MSc)
- Research Methods & Practice (BSc)
- Quantitative Methods (PhD)
- Health Care Financing (MSc)
London School of Economics
- Pharmaceutical Economics and Policy (MSc)
- Introduction to Quantitative Analysis (MSc)
- Intermediate Quantitative Analysis (MSc/PhD)
- Market Access Academy (Executive education)
Talks & service
Talks and conferences
- Technology adoption in clinical trials: a global retrospective analysis of artificial intelligence and digital-health tools, 1990–2024
- Assessing value of medicines: the example of HTA
- Do patient inputs matter? A thematic document analysis of NICE ultra-rare disease appraisals
- The role of patient organisations on research and development: evidence from rare diseases
- Leveraging pharmaceutical services to enhance NCD service delivery in LMICs: insights from Zambia
- Industry funding of patient organisations in the United Kingdom
Service
- Ad-hoc reviewer: BMJ, Health Policy, Health Policy and Technology
- Organiser, Workshop on Corruption and Conflicts of Interest in Healthcare, LSE, January 2024
- Co-founder, LSE–LSHTM Rare Diseases Reading Group, 2021–2024
- Member, Royal Economic Society